The TREATS Act amends the Controlled Substances Act (21 U.S.C. 829(e)(2)) to create an explicit telehealth evaluation pathway for prescribing FDA‑approved schedule III, IV, or V medications used to treat substance use disorders. The bill adds a telehealth option to the statute’s evaluation rule and separately defines “telehealth evaluation” to include two‑way, real‑time communications and audio‑only encounters under the telehealth standards in section 1834(m) of the Social Security Act.
This change narrows the statutory friction that has limited remote prescribing for medication‑assisted treatment (MAT), particularly medications like buprenorphine. For providers, payers, telehealth vendors, and state regulators, the bill alters compliance checks, documentation expectations, and enforcement risks while leaving several operational questions for agencies and state licensing boards to resolve.
At a Glance
What It Does
The bill amends 21 U.S.C. 829(e)(2) to add an explicit telehealth evaluation option when prescribing FDA‑approved schedule III–V drugs for substance use disorder and defines telehealth evaluation to include two‑way audio‑only and audio‑video communications consistent with 42 U.S.C. 1395m(m). It also retains the statute’s in‑person evaluation language, creating a new statutory structure for evaluations.
Who It Affects
Primary targets are clinicians who prescribe MAT (for example, office‑based buprenorphine prescribers), telehealth platforms that support controlled‑substance prescribing, insurers and Medicaid programs that reimburse telemedicine, and state medical and pharmacy boards responsible for licensure and controlled‑substance oversight.
Why It Matters
By putting a statutory telehealth option into the Controlled Substances Act, the bill reduces legal ambiguity that has constrained remote initiation and management of certain addiction medications, which could expand access in rural and underserved communities while forcing new compliance practices for prescribers and payers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The TREATS Act rewrites a piece of the Controlled Substances Act that governs how medical evaluations must occur before a practitioner may prescribe controlled substances. Concretely, it inserts a telehealth evaluation option into the statutory list of permitted evaluation formats, and separately defines what counts as a telehealth evaluation.
The definition ties the allowable technology to the telehealth standard in the Social Security Act (1834(m)), and explicitly permits audio‑only encounters alongside audio‑video sessions.
The new telehealth route is limited in scope: it applies only to controlled substances in schedules III, IV, or V that have been approved by the Food and Drug Administration for substance use disorder treatment. That means the amendment targets medications commonly used in office‑based medication‑assisted treatment (MAT) programs while leaving higher‑schedule drugs governed by other rules.
The statute also expressly excludes pharmacists from qualifying as the practitioner who may conduct these telehealth evaluations.Practically, the bill signals to clinicians and payers that remote evaluations—conducted with two‑way, real‑time audio or audio‑video systems—are acceptable for initiating or managing certain SUD medicines, subject to applicable federal and state law. However, the change is textual rather than regulatory: it does not itself create new federal billing codes, change state licensure requirements, or spell out documentation, PDMP checks, or cross‑state practice rules.
Those operational details will require agency guidance and updates to state statutes and payer policies.For treatment access, the combination of a clear statutory telehealth option and allowance for audio‑only visits reduces technical barriers for patients without broadband or video capability. For compliance, the statute adds a new line item to audit trails—telehealth evaluations must meet the defined communication standard and remain consistent with existing controlled‑substance rules—placing the onus on prescribers and organizations to align their workflows and recordkeeping.
The Five Things You Need to Know
The bill amends 21 U.S.C. 829(e)(2) to add an explicit telehealth evaluation option for prescribing controlled substances used to treat SUDs.
The telehealth option is limited to schedule III, IV, or V drugs that the FDA has approved for substance use disorder treatment (it does not expand to schedule II).
The statutory definition of “telehealth evaluation” incorporates the Social Security Act’s section 1834(m) telecommunication standard and expressly permits audio‑only encounters in addition to audio‑video communications.
Pharmacists are explicitly excluded from the list of practitioners who may perform a telehealth evaluation under the new language; the bill speaks of practitioners other than pharmacists.
The amendment preserves the statute’s in‑person evaluation language while inserting a telehealth pathway, a structural change whose practical interplay (when telehealth substitutes for versus supplements in‑person care) will likely require agency interpretation.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds a telehealth evaluation pathway to the evaluation requirement
This subsection replaces the original single line requiring “at least 1 in‑person medical evaluation” with a two‑item structure that lists an in‑person evaluation and—specifically for certain SUD prescriptions—a telehealth evaluation. The practical effect is to put a telehealth option into the statute’s mechanics for evaluations; it does not itself list documentation standards or change other sections governing prescribing. Compliance officers should note that the text creates parallel routes but doesn’t fully resolve whether telehealth may always substitute for in‑person assessment in every factual scenario.
Defines ‘telehealth evaluation’ and ties it to SSA 1834(m)
The bill adds a statutory definition that requires telehealth evaluations to use the telecommunications system described in section 1834(m) of the Social Security Act and to permit two‑way, real‑time interaction. Crucially, the definition includes audio‑only encounters as acceptable. By anchoring the definition to 1834(m) the bill imports a federal telehealth technical baseline (used in Medicare), which will interact with payer rules and state telemedicine standards when organizations define their telehealth modalities and recordkeeping practices.
Limits application to FDA‑approved SUD drugs in Schedules III–V and excludes pharmacists
The amendment confines the telehealth option to Schedule III–V drugs that the FDA has cleared for SUD treatment—language that targets medications commonly used in office‑based MAT (for example, buprenorphine) and excludes higher‑schedule medications. The statute also clarifies that a ‘‘practitioner (other than a pharmacist)’’ conducts telehealth evaluations, meaning pharmacies cannot substitute for clinicians in the evaluation step; pharmacies will still be involved in dispensing but not in performing the telehealth assessment required by this provision.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People with substance use disorder in rural or broadband‑limited areas — clearer federal permission for audio‑only and remote evaluations lowers travel and technology barriers to starting or continuing MAT.
- Office‑based MAT prescribers (e.g., X‑waivered or DATA‑waived buprenorphine prescribers) — statutory clarity reduces legal uncertainty about using telehealth to evaluate and manage patients on FDA‑approved schedule III–V SUD medications.
- Telehealth vendors and platforms — demand for compliant, HIPAA‑aligned audio‑only and two‑way communication solutions will likely rise as providers formalize remote workflows.
- Medicaid programs and private payers focused on SUD treatment access — remote evaluation can reduce missed appointments and support retention in care, which can lower downstream costs tied to overdose and acute care.
- Community health centers and rural clinics — the change makes it administratively easier to incorporate remote consults into existing MAT programs, extending specialist reach.
Who Bears the Cost
- Prescribing clinicians and health systems — they must update intake workflows, consent forms, technology, identity verification, and documentation practices to meet the new statutory pathway and reconcile state rules.
- State licensing boards and professional regulators — boards will need to revise guidance and enforcement approaches to account for statutory telehealth permission while maintaining standards of care.
- Payers and Medicaid agencies — insurers must decide reimbursement and prior‑authorization policies for audio‑only visits and may face short‑term cost increases as access expands.
- Pharmacies and pharmacists — although excluded from performing evaluations, they will need stronger verification processes for remote‑initiated prescriptions and may face operational burdens from surge in remote fills.
- Federal and state enforcement agencies (DEA, state controlled‑substance authorities) — agencies may absorb higher administrative and investigatory workloads while developing guidance and enforcement priorities.
Key Issues
The Core Tension
The bill’s central dilemma is access versus control: it expands access to evidence‑based SUD medications by permitting remote and audio‑only evaluations, addressing geographic and technology barriers, but doing so raises legitimate concerns about patient identification, clinical assessment quality, and diversion risk—trade‑offs that will fall to agencies, state boards, and payers to manage through rules and enforcement rather than by the statute alone.
The bill clears a key statutory hurdle for telehealth‑based MAT by naming an evaluation pathway and defining the technology baseline, but it leaves numerous operational questions unanswered. The text ties the telehealth standard to Medicare’s 1834(m) language and permits audio‑only care, which expands access but creates ambiguity about minimum assessment content, identity verification, and clinical thresholds that typically depend on a visual exam or in‑person interaction.
Organizations will need to reconcile the federal telehealth permission with state telemedicine statutes, which vary on audio‑only allowances, and with DEA and FDA rules governing controlled substances and safety monitoring.
Another implementation challenge is the bill’s limited scope: it applies only to schedule III–V drugs that the FDA has approved for SUD—so medications regulated differently (for example, methadone delivered through opioid treatment programs) remain governed by existing, more restrictive rules. The statute’s parallel listing of an in‑person requirement and a telehealth option creates structural uncertainty: enforcement agencies and courts may have to interpret whether telehealth can fully substitute for in‑person care in all contexts, or only in narrowly defined circumstances.
Finally, the bill does not address reimbursement, interstate licensure, PDMP usage, or record retention specifics—matters that will determine real‑world uptake and compliance costs for providers and payers.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.